B
CELG

Bailard’s Celgene Corp CELG Stock Holding History

Bailard’s Portfolio CELG Stock Details CELG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-37,208
Closed -$3.69M – 636
2019
Q3 		$3.69M Buy
37,208
+1,536
+4% +$146K 0.22% 93
2019
Q2 		$3.3M Buy
35,672
+1,898
+6% +$180K 0.2% 110
2019
Q1 		$3.19M Buy
33,774
+830
+3% +$72.6K 0.2% 109
2018
Q4 		$2.11M Sell
32,944
-4,378
-12% -$323K 0.14% 140
2018
Q3 		$3.34M Sell
37,322
-4,661
-11% -$412K 0.2% 113
2018
Q2 		$3.33M Sell
41,983
-8,025
-16% -$666K 0.2% 115
2018
Q1 		$4.46M Buy
50,008
+3,050
+6% +$293K 0.28% 87
2017
Q4 		$4.9M Buy
46,958
+45,579
+3,305% +$5.14M 0.31% 72
2017
Q3 		$201K Buy
+1,379
New +$188K 0.02% 293
2016
Q4 		– Sell
-2,223
Closed -$232K – 336
2016
Q3 		$232K Buy
+2,223
New +$241K 0.02% 290
2016
Q1 		– Sell
-5,500
Closed -$659K – 397
2015
Q4 		$659K Buy
+5,500
New +$636K 0.29% 115

Other funds holding CELG

FP
Factorial Partners Mt. Kisco, New York $138M AUM 25.59% 1-Year Est. Return
HCM
Howard Capital Management Roswell, Georgia $6.11B AUM 33.56% 1-Year Est. Return
PCMC
Private Capital Management (Colorado) Denver, Colorado $501M AUM 17.09% 1-Year Est. Return
WCG
Weaver Consulting Group Huntington Beach, California $420M AUM 14.29% 1-Year Est. Return

Bailard's CELG Position: Q4 2019 in Review

Bailard sold out of Celgene Corp (CELG) in Q4 2019, closing a stake of 37,208 shares — an estimated $3.69M sold.

Bailard first reported a position in CELG in Q4 2015 and held it in 11 quarters. The position peaked at $4.9M in Q4 2017. 4 funds tracked by Wall St. Rank hold CELG as of Q4 2019.

  • Bailard reported no remaining Celgene Corp position as of Q4 2019 after selling out during the quarter.
  • Bailard sold 37,208 Celgene Corp shares in Q4 2019, an estimated $3.69M.
  • Bailard first reported a position in Celgene Corp in Q4 2015 and held it in 11 quarters.
  • Bailard's Celgene Corp position peaked at $4.9M in Q4 2017.
  • 4 funds tracked by Wall St. Rank held Celgene Corp as of Q4 2019.

Based on Bailard's 13F filing for Q4 2019, filed 31 Jan 2020.